veldoreotide (DG3173) / Xeris Biopharma - LARVOL DELTA

Pharmacological Characterization of Veldoreotide as a Somatostatin Receptor 4 Agonist. (PubMed, Life (Basel)) - "In the BON-1 cells expressing SSTR4, veldoreotide inhibited cell proliferation more than somatostatin SS-14 (71.2% vs. 79.7%) and to a similar extent as the SSTR4 agonist J-2156 in the presence of SSTR2 and SSTR5 antagonists. Veldoreotide is a full agonist of SSTR2, SSTR4, and SSTR5."

Journal • Pain • SSTR • SSTR2 • SSTR5

[VIRTUAL] Veldoreotide (COR005) Mechanisms of Action Studies: Comparison to Octreotide and Pasireotide (ENDO-I 2020) - "In contrast, veldoreotide can activate both SST2 and SST5 receptors under otherwise identical conditions. Thus, veldoreotide is a unique SSA with full agonistic activity at the SST2, SST4, and SST5 receptors."

Neuroendocrine Tumor • Oncology • Solid Tumor • CGA, CHGA

Decarboxylative Peptide Macrocyclization through Photoredox Catalysis. (PubMed, Angew Chem Int Ed Engl) - "Linear precursors ranging from 3 to 15 amino acids cyclize effectively under this photoredox method. To demonstrate the preparative utility of this method in the context of bioactive molecules, we synthesized COR-005, a somatostatin analogue that is currently in clinical trials."

Journal • Biosimilar

Veldoreotide (COR005) Mechanisms of Action Studies: Comparison to Octreotide and Pasireotide (ENDO 2020) - "In contrast, veldoreotide can activate both SST2 and SST5 receptors under otherwise identical conditions. Thus, veldoreotide is a unique SSA with full agonistic activity at the SST2, SST4, and SST5 receptors."

CGA, CHGA